RxDoctor Payments Data

Anthony Baron, MD

Rheumatology · Warren, MINPI 1184621336

Payments from drug & device makers

$3,886in general payments, 2019–2025

Across 193 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Amgen$511
  • UCB, Inc.$195
  • Novartis$183
  • GSK$164
  • Lilly USA, LLC$162
  • plus $636 from 9 others

What the payments were for

  • Food & beverage$3,43588%
  • Education$45112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,886 in reported general payments places this provider in the 55th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,291,346
Medicare patients
315
Services billed
99,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept69$539,778
XeljanzTofacitinib Citrate28$156,501
Humira(Cf) PenAdalimumab21$151,213
Humira PenAdalimumab23$150,134
Orencia ClickjectAbatacept11$118,165
Xeljanz XrTofacitinib Citrate18$102,422
BenlystaBelimumab21$97,662
KevzaraSarilumab20$97,015
HumiraAdalimumab14$94,726
RinvoqUpadacitinib11$67,247
MethotrexateMethotrexate Sodium518$19,763
Hydroxychloroquine Sulfate111$6,727
Leflunomide59$5,105
Prednisone272$4,494
Mycophenolate Mofetil16$2,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Rinvoq$113$161,97325 claims
PfizerXeljanz$153$156,50128 claims
GSKBenlysta$164$97,66221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →